Innovating Works

EVADER

Financiado
Experimental Virology for Assessing Disease Emergence Risks
The emergence of new human pathogenic viruses from animal reservoirs is an increasing concern, but also a poorly understood process. Massive sequencing programs have been recently launched to characterize wildlife viruses, but emp... The emergence of new human pathogenic viruses from animal reservoirs is an increasing concern, but also a poorly understood process. Massive sequencing programs have been recently launched to characterize wildlife viruses, but empirical information on how these viruses function and whether they can potentially infect humans is needed. However, the isolation and culturing of wildlife viruses is too often unfeasible due to technical issues, biosafety concerns, or lack of full-length sequence information. Furthermore, we need to investigate viral emergence from an evolutionary standpoint to better understand how host-range mutants appear and adapt to human cells. To achieve these goals, we will focus on the receptor-dependent cell tropism of enveloped RNA viruses, a central and experimentally tractable process involved in viral emergence. First, we will use high-throughput gene synthesis to create hundreds of pseudoviruses coated with the envelopes of previously uncharacterized wildlife viruses belonging to different families, and we will examine their ability to infect a panel of humans cells from various tissues. This will deliver the most comprehensive landscape of viral human cell infectivity to date. Second, we will use experimental evolution, massive parallel sequencing, and site-directed mutagenesis to explore how viral envelopes diversify, undergo cell tropism shifts, and adapt to human cells. This will provide important clues about the role of spontaneous mutation in viral emergence, and may reveal repeatable evolutionary pathways that could help us improve outbreak predictability. Finally, we will use our experimental results to infer candidate cell receptors for wildlife viruses using machine learning, and to explore the feasibility of broad-range, clade-level antiviral therapies that could be used for combating emerging viruses in the future. ver más
30/04/2027
UV
2M€
Perfil tecnológico estimado
Duración del proyecto: 68 meses Fecha Inicio: 2021-08-26
Fecha Fin: 2027-04-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2021-08-26
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2020-ADG: ERC ADVANCED GRANT
Cerrada hace 4 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
UNIVERSITAT DE VALÈNCIA (ESTUDI GENERAL) No se ha especificado una descripción o un objeto social para esta compañía.
Sin perfil tecnológico